Literature DB >> 33247807

A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?

Claire Pluchart1,2,3, Coralie Barbe4, Gael Poitevin5, Sandra Audonnet6, Philippe Nguyen5,7.   

Abstract

In paediatric acute lymphoblastic leukaemia (ALL), focus has shifted towards preventing treatment-related complications, including venous thromboembolism, the cause of significant mortality and morbidity. To better understand thrombogenic mechanisms during induction treatment, we studied the number, origin and procoagulant activity of extracellular vesicles (EVs) and P-selectin level throughout the induction course in 24 paediatric patients. EVs were mainly of platelet origin. We observed a significant increase in EV number, in platelet EV number and P-selectin level throughout the induction course. There was a correlation between higher EV and platelet EV number, P-selectin level, higher platelet count and leucocyte count. We also observed a correlation between higher EV procoagulant activity and higher platelet count and leucocyte count and higher P-selectin level. Older age and T phenotype were associated with a higher EV procoagulant activity. Platelet EV generation may play a role in thrombogenic complications in ALL patients and could serve as a biomarker to identify patients with a high risk of thrombosis. As a marker of platelet activation, P-selectin may be another relevant marker with the advantage of being easier to analyse in clinical practice.

Entities:  

Keywords:  Acute lymphoblastic leukaemia; Extracellular vesicles; Platelets; Venous thromboembolism

Year:  2020        PMID: 33247807     DOI: 10.1007/s11239-020-02346-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  34 in total

1.  Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.

Authors:  Lesley Mitchell; Moritz Lambers; Silke Flege; Gili Kenet; Valerie Li-Thiao-Te; Susanne Holzhauer; Christoph Bidlingmaier; Michael C Frühwald; Christine Heller; Wolfgang Schmidt; Brigitte Pautard; Ulrike Nowak-Göttl
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

Review 2.  Thrombosis in pediatric patients with leukemia.

Authors:  Sarina Levy-Mendelovich; Assaf Arie Barg; Gili Kenet
Journal:  Thromb Res       Date:  2018-04       Impact factor: 3.944

Review 3.  Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment).

Authors:  Rachael Hough; Ajay Vora
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years.

Authors:  Cecilie Utke Rank; Nina Toft; Ruta Tuckuviene; Kathrine Grell; Ove Juul Nielsen; Thomas Leth Frandsen; Hanne Vibeke Hansen Marquart; Birgitte Klug Albertsen; Ulf Tedgård; Helene Hallböök; Ellen Ruud; Kirsten Brunsvig Jarvis; Petter Quist-Paulsen; Pasi Huttunen; Ulla Wartiovaara-Kautto; Ólafur Gísli Jónsson; Sonata Saulyte Trakymiene; Laimonas Griškevičius; Kadri Saks; Mari Punab; Kjeld Schmiegelow
Journal:  Blood       Date:  2018-04-16       Impact factor: 22.113

5.  The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.

Authors:  Rachael F Grace; Suzanne E Dahlberg; Donna Neuberg; Stephen E Sallan; Jean M Connors; Ellis J Neufeld; Daniel J Deangelo; Lewis B Silverman
Journal:  Br J Haematol       Date:  2011-01-07       Impact factor: 6.998

Review 6.  Supportive care in pediatric cancer: the road to prevention of thrombosis.

Authors:  C Heleen van Ommen; Anthony K C Chan
Journal:  Semin Thromb Hemost       Date:  2014-03-05       Impact factor: 4.180

7.  Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study.

Authors:  R Tuckuviene; S Ranta; B K Albertsen; N G Andersson; M D Bendtsen; T Frisk; M W Gunnes; J Helgestad; M M Heyman; O G Jonsson; A Mäkipernaa; K Pruunsild; U Tedgård; S S Trakymiene; E Ruud
Journal:  J Thromb Haemost       Date:  2016-01-30       Impact factor: 5.824

Review 8.  Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer.

Authors:  K Date; C Ettelaie; A Maraveyas
Journal:  J Thromb Haemost       Date:  2017-11-08       Impact factor: 5.824

9.  Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.

Authors:  Veerle Mondelaers; Stefan Suciu; Barbara De Moerloose; Alina Ferster; Françoise Mazingue; Geneviève Plat; Karima Yakouben; Anne Uyttebroeck; Patrick Lutz; Vitor Costa; Nicolas Sirvent; Emmanuel Plouvier; Martine Munzer; Maryline Poirée; Odile Minckes; Frédéric Millot; Dominique Plantaz; Philip Maes; Claire Hoyoux; Hélène Cavé; Pierre Rohrlich; Yves Bertrand; Yves Benoit
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

10.  THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.

Authors:  Jeanette Greiner; Martin Schrappe; Alexander Claviez; Martin Zimmermann; Charlotte Niemeyer; Reinhard Kolb; Wolfgang Eberl; Frank Berthold; Eva Bergsträsser; Astrid Gnekow; Elisabeth Lassay; Peter Vorwerk; Melchior Lauten; Axel Sauerbrey; Johannes Rischewski; Andreas Beilken; Günter Henze; Wolfgang Korte; Anja Möricke
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

View more
  1 in total

1.  Circulating Extracellular Vesicles Are Strongly Associated With Cardiovascular Risk Markers.

Authors:  Ruihan Zhou; Esra Bozbas; Keith Allen-Redpath; Parveen Yaqoob
Journal:  Front Cardiovasc Med       Date:  2022-05-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.